Koc 2009

Methods	Individual randomised controlled trials
Participants	Diagnosis: SebDerm Exclusion criteria: patients with severe SebDerm, other skin conditions including psoriasis and acne; patients allergic to chemicals used in shampoos; patients who have used systemic treatments for SD within the past month Implied from context that this was SD of the face Sex: M (34/38); age: 21 to 42 years
Interventions	Intervention: pimecrolimus 1% cream applied twice daily for 42 days (n = 23) Control: ketoconazole 2% cream applied twice daily for 42 days (n = 25)
Outcomes	Symptom severity score for erythema and scaling at 12 weeks
Notes	Country: Turkey Adverse effects: keto (1/24), hydrocortisone (2/26)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Patients were randomized into two treatment groups according to a random digits table" (page 5)
Allocation concealment (selection bias)	High risk	"In this 6 week open label, randomized comparative study ..."
Baseline comparable?	Low risk	"The treatment groups were not statistically significantly different at baseline with respect to age, sex, mean disease duration and with regards to the criteria (erythema, scaling and infiltration) (p = 0.05)" (page 5)
Patient blinded?	High risk	"In this 6 week open label, randomized comparative study ..."
Provider blinded?	High risk	"In this 6 week open label, randomized comparative study ..."
Outcome assessor blinded?	High risk	"In this 6 week open label, randomized comparative study ..."
Co-interventions avoided?	Low risk	"No other medications for SD were allowed during the trial, except for anti-dandruff shampoos started more than 1 month in advance and not used on the face" (page 5)
Compliance acceptable?	Unclear risk	Not reported
Drop-out acceptable?	Low risk	Pimecrolimus 5/21, ketoconazole 4/22 (page XX)
Selective outcome reporting acceptable?	Low risk	All outcomes reported
ITT?	High risk	Not reported